

DAFTAR PUSTAKA

1. Ishaq H, Patel BC. Retinoblastoma. National Institute of Health. 2022; 1-9.
2. Kaewkhaw R, Rojanaporn D. Retinoblastoma: Etiology, modeling, and treatment. *Cancers*. 2020;12:1–23.
3. Orjuela-Grimm M, Singh N, Bhatt-Carreño S, Singh AD. Retinoblastoma: incidence and etiologic factors. In: *Clinical Ophthalmic Oncology*. Springer International Publishing; 2019. p. 39–56.
4. Jain M, Rojanaporn D, Chawla B, Sundar G, Gopal L, Khetan V. Retinoblastoma in Asia. *Eye*. 2019;33:87–96.
5. Tan RJD, Umerez DC, Alindayu JIA, Conjares JMRRM, Go DAD, Paulino RGT. Retinoblastoma in South Asia: A scoping review. *Asian Pac J Cancer Care*. 2021;6:493–500.
6. Rahman A, Tiffani D. The impact of socioeconomic factors in retinoblastoma. *European Alliance for Innovation*; 2019; 1-7.
7. Rao R, Honavar SG. Retinoblastoma. *Indian J Pediatr*. 2017;84:937–44.
8. Tomar AS, Finger PT, Gallie B, Kivelä TT, Malliparna A, Zhang C, et al. Global retinoblastoma treatment outcomes: Association with national income level. *Ophthalmology*. 2021;128:740–53.
9. Handayani K, Indraswari BW, Sitaresmi MN, Mulatsih S, Widjajanta PH, Kors WA, et al. Treatment outcome of children with retinoblastoma in a tertiary care referral hospital in Indonesia. *Asian Pac J Cancer Prev*. 2021;22:1613–21.
10. Mattosinho CCDS, Moura ATMS, Oigman G, Ferman SE, Grigorovski N. Time to diagnosis of retinoblastoma in Latin America: A systematic review. *Pediatr Hematol Oncol*. 2019;36:55–72.
11. Diakatou V, Vassilakou T. Nutritional status of pediatric cancer patients at diagnosis and correlations with treatment clinical outcome and the long-term growth and health of survivors. *Children*. 2020;8:70.
12. Zhou Y, Cai S, Jin M, Wang C, Xu N, Duan C, et al. Economic burden for retinoblastoma patients in China. *J Med Econ*. 2020;23:1553–7.
13. Mattosinho C, Moura AT, Grigorovski N, Araújo LH, Ferman S, Ribeiro K. Socioeconomic status and retinoblastoma survival: Experience of a tertiary cancer center in Brazil. *Pediatr Blood Cancer*. 2021;68: e28757.
14. Asina Miranda G, Simanjuntak GWS. Clinical findings and demography of retinoblastoma in a tertiary hospital in a remote area in a developing country. *Asian Pac J Cancer Care*. 2018;3:37.
15. Shah A, Leahey A. Retinoblastoma. In: Lanzkowsky P, Lipton JM, Fish JD, editors. *Lanzkowsky's manual of pediatric hematology and oncology*. 7th ed. London: Elsevier; 2022. p. 583-95.
16. Budny A, Grochowski C. Retinoblastoma. *J Educ Health Sport*. 2018;8:204–13.
17. Shields CL, Lally SE. Retinoblastoma. In: *Clinical Ophthalmic Oncology*. Springer; 2019. p. 91–9.

18. Fabian ID, Abdallah E, Abdullahi SU, Abdulqader RA, Adamou Boubacar S, Ademola-Popoola DS, et al. Global retinoblastoma presentation and analysis by national income level. *JAMA Oncol.* 2020;6:685–95.
19. Yousef YA, Al-Nawaiseh I, Mehryar M, Sultan I, Al-Hussaini M, Jaradat I, et al. How telemedicine and centralized care changed the natural history of retinoblastoma in a developing country: Analysis of 478 patients. *Ophthalmology.* 2021;128:130–7.
20. Jakob S, Dewa S, Hamid I. Profile of retinoblastoma in East Java, Indonesia. *Afr J Intern Med.* 2019;7:495–500.
21. Pallysater D. Profile of retinoblastoma patients at H. Adam Malik RSUP 2014–2017. *J Basic Sci Technol.* 2020;9:9–16.
22. Shakeel O, Pace N, Chambers TM, Scheurer ME, Ganguly AA, Lupo PJ, et al. Medical radiation exposure and risk of sporadic retinoblastoma. *Pediatr Blood Cancer.* 2020;67:e28633.
23. Azary S, Ganguly A, Bunin GR, Lombardi C, Park AS, Ritz B, et al. Sporadic retinoblastoma and parental smoking and alcohol consumption before and after conception: A report from the children's oncology group. *PLoS One.* 2016;11:1–16.
24. Lombardi C, Ganguly A, Bunin GR, Azary S, Alfonso V, Ritz B, et al. Maternal diet during pregnancy and unilateral retinoblastoma. *Cancer Causes Control.* 2015;26:387–97.
25. Randhawa JK, Kim ME, Polski A, Reid MW, Mascarenhas K, Brown B, et al. The effects of breastfeeding on retinoblastoma development: Results from an international multicenter retinoblastoma survey. *Cancers.* 2021;13:1–11.
26. Javanmard D, Moein M, Esghaei M, Nasenpour M, Monavari SH, Bokharaei-Salim F, et al. Molecular evidence of human papillomaviruses in the retinoblastoma tumor. *Virusdisease.* 2019;30:360–6.
27. Soltani S, Tabibzadeh A, Yousefi P, Zandi M, Zakeri A, Akhavan Rezayat S, et al. HPV infections in retinoblastoma: A systematic review. *J Clin Lab Anal.* 2021;35.
28. Singh L, Kashyap S. Update on pathology of retinoblastoma. *Int J Ophthalmol.* 2018;11:2011–6.
29. Pizzo PA, Poplack DG. *Principles and Practice of Pediatric Oncology.* 7th ed. Wolters Kluwer; 2015.
30. AlAli A, Kletke S, Galie B, Wai-Ching L. Retinoblastoma for pediatric ophthalmologists. *Asia Pac J Ophthalmol.* 2018;7:160–8.
31. Lin FY, Chintagumpala MM. Neonatal retinoblastoma. *Clin Perinatol.* 2021;48:53–70.
32. Kementerian Kesehatan Republik Indonesia. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Retinoblastoma.* Jakarta: Kementerian Kesehatan Republik Indonesia; 2022.
33. Silvera VM, Guerin JB, Brinjikji W, Dalvin LA. Retinoblastoma: What the neuroradiologist needs to know. *Am J Neuroradiol.* 2021;42:618–26.
34. Gupta S, Kaliki S. Current management in retinoblastoma. In: *Current Management in Ophthalmology.* Springer; 2019:1–22.
35. Tan RJD. Clinical features, treatment, and outcomes of retinoblastoma in China. *Asian J Oncol.* 2022;8:127–35.
36. Finger PT, Tomar AS. Retinoblastoma outcomes: A global perspective. *Lancet Glob Health.* 2022;10:307–8.

37. Stacey AW, Bowman R, Foster A, Kivelä TT, Munier FL, Cassoux N, et al. Incidence of retinoblastoma has increased: Results from 40 European countries. *Ophthalmology*. 2021;128:1369–71.
38. The Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: A prospective, cluster-based analysis of 4064 patients from 149 countries. *Lancet Glob Health*. 2022;10.
39. Chen PY, Kao LY, Chao AN, Wu WC, Sun MH, Su WW, et al. Retinoblastoma in Taiwan: Survival and clinical characteristics. *Jpn J Ophthalmol*. 2021;65:546–53.
40. Gupta SK, Meshram M, Kumar A, Verma N, Agrawal S, Kumar A. Survival and outcome of retinoblastoma treated by neo-adjuvant chemotherapy in India. *Cancer Rep*. 2019;2:e1137.
41. Kaliki S, Ji X, Zou Y, Rashid R, Sultana S, Sherief ST, et al. Lag time between onset of first symptom and treatment of retinoblastoma: An international collaborative study of 692 patients from 10 countries. *Cancers (Basel)*. 2021;13:1956.
42. Singh G, Daniels AB. Disparities in retinoblastoma presentation, treatment, and outcomes in developed and less-developed countries. *Semin Ophthalmol*. 2016;31:310–6.
43. Johnston WT, Erdmann F, Newton R, Steliarova-Foucher E, Schüz J, Roman E. Childhood cancer: Estimating regional and global incidence. *Cancer Epidemiol*. 2021;7: 101662.
44. Issaq SH, Heske CM. Targeting metabolic dependencies in pediatric cancer. *Curr Opin Pediatr*. 2020;32:26–34.
45. Rosen GP, Beebe KL, Shaibi GQ. Vitamin D levels differ by cancer diagnosis and decline over time in survivors of childhood cancer. *Pediatr Blood Cancer*. 2013;60:949–52.
46. Zia N, Hamid A, Iftikhar S, Qadri MH, Jangda A, Khan MR. Retinoblastoma presentation and survival: A four-year analysis from a tertiary care hospital. *Pak J Med Sci*. 2020;36:S61–6.
47. Handayani K, Sitaresmi MN, Supriyadi L, Widhiyanto PH, Susilawati D, Njuguna F, et al. Delays in diagnosis and treatment of childhood cancer in Indonesia. *Pediatr Blood Cancer*. 2016;63:2189–96.
48. Dharmawidhiarini D, Soebagjo D. Ocular survival rate penderita retinoblastoma yang telah dilakukan enukleasi atau eksenterasi di RSUD Dr. Soetomo Surabaya. *J Oftalmol Indones JOI*. 2010;7:1–6.
49. Ghassemi F, Khodabande A. Risk definition and management strategies in retinoblastoma: Current perspectives. *Clin Ophthalmol*. 2015;9:985–94.
50. Balasopoulou A, Kokkinos P, Pagoulatos D, Plotas P, Makri OE, Georgakopoulos CD, et al. Recent advances and challenges in the management of retinoblastoma: Globe-saving treatments. *BMC Ophthalmol*. 2017;17:1–14.
51. Fabian ID, Onadim Z, Karaa E, Duncan C, Chowdhury T, Scheimberg I, et al. The management of retinoblastoma. *Oncogene*. 2018;37:1551–60.
52. Wong ES, Choy RW, Zhang Y, Chu WK, Chen LJ, Pang CP, et al. Global retinoblastoma survival and globe preservation: A systematic review and meta-analysis of associations with socioeconomic and health-care factors. *Lancet Glob Health*. 2022;10:380–9.



53. Abramson DH, Fabius AWM, Issa R, Francis JH, Marr BP, Dunkel IJ, et al. Advanced unilateral retinoblastoma: The impact of ophthalmic artery chemosurgery on enucleation rate and patient survival at MSKCC. *PLoS One*. 2015;10:e0145436.
54. Mehyar M, Mosallam M, Tbakhi A, Saab A, Sultan I, Deebajah R, et al. Impact of RB1 gene mutation type in retinoblastoma patients on clinical presentation and management outcome. *Hematol Oncol Stem Cell Ther*. 2020;13:152–9.
55. Yu LR, Li WP, Zhang CC, Gong Q, Lu Y, Zhou LH. Analysis of prognosis and quality of life in children with retinoblastoma. *Int J Ophthalmol*. 2025;18:2312–8.
56. Atima MO, Idakwo U, Komolafe O, Eisuke S, Shintaro N, Balogun EO, et al. Presentation pattern and survival rate of retinoblastoma following chemotherapy: a prospective study. *BMC Pediatr*. 2023;23:538.
57. Fabian ID, Khetan V, Stacey AW, Foster A, Ademola-Popoola DS, Berry JL, et al. Sex, gender, and retinoblastoma: analysis of 4351 patients from 153 countries. *Eye (Lond)*. 2022;36:1571–7.
58. Ribeiro KB, Veiga LHS, Carvalho Filho HA, Morton LM, Kleinerman RA, Antoneli CBG. Overall survival and cause-specific mortality in a hospital-based cohort of retinoblastoma patients in São Paulo, Brazil. *Int J Cancer*. 2025;156:69–78.
59. Berry JL, Pike S, Rajagopalan A, Reid MW, Fabian ID. Retinoblastoma outcomes in the Americas: a prospective analysis of 491 children with retinoblastoma from 23 American countries. *Am J Ophthalmol*. 2024;260:91–101.
60. Das S, Mahajan A, Das S, Honavar SG. Survival outcomes and globe salvage rates of retinoblastoma in India: a systematic review. *Indian J Ophthalmol*. 2025;73:1116–23.
61. Nindyastuti H, Rusmawatiningsih D, Makrufardi F, Supriyadi E. Lag time to diagnosis as a predictor of mortality in children with extraocular retinoblastoma: experience from a developing country. *Asia Pac J Clin Oncol*. 2022;18:706–13.
62. Makamo N, Schoon S, Ozuah N, Kaspers G, Ladas EJ, Huibers M. Prevalence of undernutrition in children with cancer in low-income and middle-income countries: a systematic review. *BMJ Glob Health*. 2025;10:eArticle number not assigned.
63. Chen J, Cao X, Xu S, Chen X, Xie R, Ye G, et al. Global, regional, and national burden of retinoblastoma in infants and young children: findings from the Global Burden of Disease Study 1990–2021. *EClinicalMedicine*. 2024;46:102860.
64. Utomo PT, Respatika D, Ardiansyah B, Rumania UT, Heriyanto DS, Dibyasakti BA, et al. Lag time, high-risk histopathological features, metastasis, and survival interrelation in retinoblastoma: a perspective from a lower-middle-income country. *Int J Ophthalmol*. 2022;15(12):1994–2000.